Mesenchymal Cell News Volume 4.26 | Jul 3 2012

May 12, 2022

Mesenchymal Cell News 4.26 July 3, 2012

In this issue: Publications | Industry News | Policy News | Events | Jobs

TOP STORY

Mesenchymal Stem Cells Neither Fully Acquire the Electrophysiological Properties of Mature Cardiomyocytes Nor Promote Ventricular Arrhythmias in Infarcted Rats
Researchers investigated electrophysiological properties and proarrhythmic effects of mesenchymal stem cells in infarcted hearts. [Basic Res Cardiol] Abstract

PUBLICATIONS (Ranked by impact factor of the journal)

Noggin Suppression Decreases BMP-2-Induced Osteogenesis of Human Bone Marrow-Derived Mesenchymal Stem Cells In Vitro
Investigators examined the effects of noggin suppression on viability and bone morphogenetic protein-2 (BMP-2)-induced osteogenic differentiation of human bone marrow-derived mesenchymal stem cells in vitro. [J Cell Biochem] Abstract

Mesenchymal Stem Cell Graft Improves Recovery after Spinal Cord Injury in Adult Rats through Neurotrophic and Pro-Angiogenic Actions
Researchers aimed to graft mesenchymal stem cells after a spinal cord compression injury in adult rat to assess their effect on functional recovery and to highlight their mechanisms of action. [PLoS One] Full Article

Efficient Engineering of Vascularized Ectopic Bone from Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells
Scientists developed efficient and reproducible directed differentiation systems toward human mesenchymal stem cells from human embryonic stem cells, including co-culture with murine OP9 stromal cells and feeder layer-free. [Tissue Eng Part A] Abstract

Adipose Derived Mesenchymal Stem Cell Transplantation via Portal Vein Improves Microcirculation and Ameliorates Liver Fibrosis Induced by CCl4 in Rats
Researchers investigated the therapeutic potential of adipose derived mesenchymal stem cell transplantation in liver fibrosis caused by carbon tetrachloride (CCl4) in rats as well as its underlying mechanism, and explored the appropriate infusion pathway. [J Transl Med] Abstract | Full Article

Bone Marrow Mesenchymal Stem Cells, Platelet-Rich Plasma and Nanohydroxyapatite-Type I Collagen Beads Were Integral Parts of Biomimetic Bone Substitutes for Bone Regeneration
Researchers used a rabbit model to combine platelet rich plasma (PRP), nanohydroxyapatite-type I collagen beads (CIB) and bone marrow mesenchymal stem cells (BMSCs) into a bone-like substitute to study its impact on bone regeneration, when compared to defect alone, PRP, CIB plus PRP, and PRP plus BMSC. [J Tissue Eng Regen Med] Abstract

SOX9 Gene Transfer via Safe, Stable, Replication-Defective Recombinant Adeno-Associated Virus Vectors as a Novel, Powerful Tool to Enhance the Chondrogenic Potential of Human Mesenchymal Stem Cells
Scientists evaluated the benefits of delivering SOX9 via safe, maintained, replication-defective recombinant adeno-associated virus vector upon the capability of human bone marrow-derived mesenchymal stem cells to commit towards an adequate chondrocyte phenotype vis-a-vis other mesenchymal lineages. [Stem Cell Res Ther] Abstract | Full Article

Chondrogenesis of Human Bone Marrow Mesenchymal Cells by Transforming Growth Factors ß1 through Cell Shape Changes on Controlled Biomaterials
The phenotypic responses of human bone marrow mesenchymal cells on different ratios of chitosan/polycaprolactone blends were investigated in this study. [J Biomed Mater Res A] Abstract

INDUSTRY NEWS

Harvard Bioscience’s “InBreath” Bioreactors Used in World’s First Successful Regenerated Laryngotracheal Transplants
Harvard Bioscience, Inc. announced that its “InBreath” bioreactors were used for the world’s first and second successful laryngotracheal implants, using synthetic laryngotracheal scaffolds seeded with cells taken from the patients’ bone marrow. [Harvard Bioscience, Inc.] Press Release

Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart Attack
Osiris Therapeutics, Inc. announced interim one-year results from its groundbreaking clinical trial evaluating Prochymal^® for the treatment of patients experiencing first-time acute myocardial infarction. [Osiris Therapeutics, Inc.] Press Release

Osiris Bolsters Its Stem Cell Intellectual Property Estate
Osiris Therapeutics, Inc. announced the expansion of its intellectual property protection around Prochymal^®. The United States Patent and Trademark Office granted Osiris two patents that cover multiple mechanisms of action related to cardiac tissue repair. [Osiris Therapeutics, Inc.] Press Release